7Kuemmerle-Deschner JB,Horneff G.Safety and efficacy of once-weekly application of etanercept in children with juvenile idiopathic arthritis[J].Rheumatol Int,2007,28(2):153-156.
8Horneff G,Ebert A,Fitter S,et al.Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis[J].Rheumatology (Oxford),2009,48(8):916-919.
9Yim DS,Zhou H,Buckwalter M,et al.Population pharma-cokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis[J].J Clin Pharmacol,2005,45(3):246-256.
10Giannini EH,Ruperto N,Ravelli A,et al.Preliminary definition of improvement in juvenile arthritis[J].Arthritis Rheum,1997,40(7):1202-1209.
6Burgos-Vargas R.The juvenile-onset spondyloarthritides[J].Rheum Dis Clin N Am,2002,28(3):531-560.
7Grom A A,Murray K J,Luyrink L,et al.Patterns of expression of tumor necrosis factor-a and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy[J].Arthritis Rheum,1996,39(10):1703-1710.
8Kietz D A,Pepmueller P H,Moore T L.Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period[J].Ann Rheum Dis,2002,61(2):171-173.
9Davis JC Jr,Van Der Heijde D,Braun J,et al.Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis:a randomized,controlled trial[J].Arthritis Rheum,2003,48(11):3230-3236.
10Dougados M,van der Linden S,Juhlin R,et al.The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy[J].Arthritis Rheum,1991,34(10):1218-1227.
